PMC:7243768 / 41781-42844 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"1611","span":{"begin":5,"end":15},"obj":"Species"},{"id":"1624","span":{"begin":272,"end":282},"obj":"Species"},{"id":"1625","span":{"begin":567,"end":575},"obj":"Species"},{"id":"1626","span":{"begin":651,"end":661},"obj":"Species"},{"id":"1627","span":{"begin":382,"end":394},"obj":"Disease"},{"id":"1628","span":{"begin":399,"end":412},"obj":"Disease"},{"id":"1629","span":{"begin":548,"end":556},"obj":"Disease"},{"id":"1630","span":{"begin":557,"end":566},"obj":"Disease"},{"id":"1631","span":{"begin":584,"end":590},"obj":"Disease"},{"id":"1632","span":{"begin":592,"end":600},"obj":"Disease"},{"id":"1633","span":{"begin":606,"end":614},"obj":"Disease"},{"id":"1634","span":{"begin":839,"end":854},"obj":"Disease"},{"id":"1635","span":{"begin":895,"end":914},"obj":"Disease"}],"attributes":[{"id":"A1611","pred":"tao:has_database_id","subj":"1611","obj":"Tax:2697049"},{"id":"A1624","pred":"tao:has_database_id","subj":"1624","obj":"Tax:2697049"},{"id":"A1625","pred":"tao:has_database_id","subj":"1625","obj":"Tax:9606"},{"id":"A1626","pred":"tao:has_database_id","subj":"1626","obj":"Tax:2697049"},{"id":"A1627","pred":"tao:has_database_id","subj":"1627","obj":"MESH:D007249"},{"id":"A1628","pred":"tao:has_database_id","subj":"1628","obj":"MESH:D003711"},{"id":"A1629","pred":"tao:has_database_id","subj":"1629","obj":"MESH:C000657245"},{"id":"A1630","pred":"tao:has_database_id","subj":"1630","obj":"MESH:D007239"},{"id":"A1631","pred":"tao:has_database_id","subj":"1631","obj":"MESH:D009325"},{"id":"A1632","pred":"tao:has_database_id","subj":"1632","obj":"MESH:D014839"},{"id":"A1633","pred":"tao:has_database_id","subj":"1633","obj":"MESH:D006261"},{"id":"A1634","pred":"tao:has_database_id","subj":"1634","obj":"MESH:D001102"},{"id":"A1635","pred":"tao:has_database_id","subj":"1635","obj":"MESH:D012140"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"6.7 SARS-CoV-2-CNS risk\nMathew reported that it might be due to the obstructions in the nervous system, which may restrict the entry of air into the lungs [108]. The virus enters the medullary neurons during the latency phase. A possible mechanism explained was that the SARS-CoV-2 might enter the olfactory lobe of the brain through nasal chambers upon inhalation and may lead to inflammation and demyelination. Later, it spreads to the whole brain due to its ability to cross the blood-brain barrier. Some neurological symptoms exhibited by the COVID-19 infection patients include nausea, vomiting, and headache (represented in Table 1). Since the SARS-CoV-2 possess the ability to cross the blood-brain barrier, it is important to design the drugs in such a way that they can cross the blood-brain barrier and scavenges the brain from viral infection. Also, it is essential to note that the respiratory illness accompanies neurological invasion by the virus, therapeutic care must be taken to prevent the viral entry into the central nervous system (CNS) [7]."}

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T358","span":{"begin":16,"end":19},"obj":"Body_part"},{"id":"T359","span":{"begin":89,"end":103},"obj":"Body_part"},{"id":"T360","span":{"begin":150,"end":155},"obj":"Body_part"},{"id":"T361","span":{"begin":194,"end":201},"obj":"Body_part"},{"id":"T362","span":{"begin":321,"end":326},"obj":"Body_part"},{"id":"T363","span":{"begin":445,"end":450},"obj":"Body_part"},{"id":"T364","span":{"begin":483,"end":488},"obj":"Body_part"},{"id":"T365","span":{"begin":489,"end":494},"obj":"Body_part"},{"id":"T366","span":{"begin":695,"end":700},"obj":"Body_part"},{"id":"T367","span":{"begin":701,"end":706},"obj":"Body_part"},{"id":"T368","span":{"begin":790,"end":795},"obj":"Body_part"},{"id":"T369","span":{"begin":796,"end":801},"obj":"Body_part"},{"id":"T370","span":{"begin":828,"end":833},"obj":"Body_part"},{"id":"T371","span":{"begin":1030,"end":1052},"obj":"Body_part"},{"id":"T372","span":{"begin":1054,"end":1057},"obj":"Body_part"}],"attributes":[{"id":"A358","pred":"fma_id","subj":"T358","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A359","pred":"fma_id","subj":"T359","obj":"http://purl.org/sig/ont/fma/fma7157"},{"id":"A360","pred":"fma_id","subj":"T360","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A361","pred":"fma_id","subj":"T361","obj":"http://purl.org/sig/ont/fma/fma54527"},{"id":"A362","pred":"fma_id","subj":"T362","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A363","pred":"fma_id","subj":"T363","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A364","pred":"fma_id","subj":"T364","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A365","pred":"fma_id","subj":"T365","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A366","pred":"fma_id","subj":"T366","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A367","pred":"fma_id","subj":"T367","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A368","pred":"fma_id","subj":"T368","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A369","pred":"fma_id","subj":"T369","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A370","pred":"fma_id","subj":"T370","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A371","pred":"fma_id","subj":"T371","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A372","pred":"fma_id","subj":"T372","obj":"http://purl.org/sig/ont/fma/fma55675"}],"text":"6.7 SARS-CoV-2-CNS risk\nMathew reported that it might be due to the obstructions in the nervous system, which may restrict the entry of air into the lungs [108]. The virus enters the medullary neurons during the latency phase. A possible mechanism explained was that the SARS-CoV-2 might enter the olfactory lobe of the brain through nasal chambers upon inhalation and may lead to inflammation and demyelination. Later, it spreads to the whole brain due to its ability to cross the blood-brain barrier. Some neurological symptoms exhibited by the COVID-19 infection patients include nausea, vomiting, and headache (represented in Table 1). Since the SARS-CoV-2 possess the ability to cross the blood-brain barrier, it is important to design the drugs in such a way that they can cross the blood-brain barrier and scavenges the brain from viral infection. Also, it is essential to note that the respiratory illness accompanies neurological invasion by the virus, therapeutic care must be taken to prevent the viral entry into the central nervous system (CNS) [7]."}

LitCovid-PD-UBERON

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T494","span":{"begin":5,"end":13},"obj":"Disease"},{"id":"T495","span":{"begin":5,"end":9},"obj":"Disease"},{"id":"T496","span":{"begin":272,"end":280},"obj":"Disease"},{"id":"T497","span":{"begin":272,"end":276},"obj":"Disease"},{"id":"T498","span":{"begin":382,"end":394},"obj":"Disease"},{"id":"T499","span":{"begin":548,"end":556},"obj":"Disease"},{"id":"T500","span":{"begin":557,"end":566},"obj":"Disease"},{"id":"T501","span":{"begin":651,"end":659},"obj":"Disease"},{"id":"T502","span":{"begin":651,"end":655},"obj":"Disease"},{"id":"T503","span":{"begin":839,"end":854},"obj":"Disease"},{"id":"T504","span":{"begin":845,"end":854},"obj":"Disease"}],"attributes":[{"id":"A494","pred":"mondo_id","subj":"T494","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A495","pred":"mondo_id","subj":"T495","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A496","pred":"mondo_id","subj":"T496","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A497","pred":"mondo_id","subj":"T497","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A498","pred":"mondo_id","subj":"T498","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A499","pred":"mondo_id","subj":"T499","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A500","pred":"mondo_id","subj":"T500","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A501","pred":"mondo_id","subj":"T501","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A502","pred":"mondo_id","subj":"T502","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A503","pred":"mondo_id","subj":"T503","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A504","pred":"mondo_id","subj":"T504","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"6.7 SARS-CoV-2-CNS risk\nMathew reported that it might be due to the obstructions in the nervous system, which may restrict the entry of air into the lungs [108]. The virus enters the medullary neurons during the latency phase. A possible mechanism explained was that the SARS-CoV-2 might enter the olfactory lobe of the brain through nasal chambers upon inhalation and may lead to inflammation and demyelination. Later, it spreads to the whole brain due to its ability to cross the blood-brain barrier. Some neurological symptoms exhibited by the COVID-19 infection patients include nausea, vomiting, and headache (represented in Table 1). Since the SARS-CoV-2 possess the ability to cross the blood-brain barrier, it is important to design the drugs in such a way that they can cross the blood-brain barrier and scavenges the brain from viral infection. Also, it is essential to note that the respiratory illness accompanies neurological invasion by the virus, therapeutic care must be taken to prevent the viral entry into the central nervous system (CNS) [7]."}

LitCovid-PD-CLO

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T207","span":{"begin":746,"end":751},"obj":"Chemical"}],"attributes":[{"id":"A207","pred":"chebi_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"6.7 SARS-CoV-2-CNS risk\nMathew reported that it might be due to the obstructions in the nervous system, which may restrict the entry of air into the lungs [108]. The virus enters the medullary neurons during the latency phase. A possible mechanism explained was that the SARS-CoV-2 might enter the olfactory lobe of the brain through nasal chambers upon inhalation and may lead to inflammation and demyelination. Later, it spreads to the whole brain due to its ability to cross the blood-brain barrier. Some neurological symptoms exhibited by the COVID-19 infection patients include nausea, vomiting, and headache (represented in Table 1). Since the SARS-CoV-2 possess the ability to cross the blood-brain barrier, it is important to design the drugs in such a way that they can cross the blood-brain barrier and scavenges the brain from viral infection. Also, it is essential to note that the respiratory illness accompanies neurological invasion by the virus, therapeutic care must be taken to prevent the viral entry into the central nervous system (CNS) [7]."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T60","span":{"begin":382,"end":394},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T61","span":{"begin":839,"end":854},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"6.7 SARS-CoV-2-CNS risk\nMathew reported that it might be due to the obstructions in the nervous system, which may restrict the entry of air into the lungs [108]. The virus enters the medullary neurons during the latency phase. A possible mechanism explained was that the SARS-CoV-2 might enter the olfactory lobe of the brain through nasal chambers upon inhalation and may lead to inflammation and demyelination. Later, it spreads to the whole brain due to its ability to cross the blood-brain barrier. Some neurological symptoms exhibited by the COVID-19 infection patients include nausea, vomiting, and headache (represented in Table 1). Since the SARS-CoV-2 possess the ability to cross the blood-brain barrier, it is important to design the drugs in such a way that they can cross the blood-brain barrier and scavenges the brain from viral infection. Also, it is essential to note that the respiratory illness accompanies neurological invasion by the virus, therapeutic care must be taken to prevent the viral entry into the central nervous system (CNS) [7]."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T288","span":{"begin":0,"end":24},"obj":"Sentence"},{"id":"T289","span":{"begin":25,"end":162},"obj":"Sentence"},{"id":"T290","span":{"begin":163,"end":227},"obj":"Sentence"},{"id":"T291","span":{"begin":228,"end":413},"obj":"Sentence"},{"id":"T292","span":{"begin":414,"end":503},"obj":"Sentence"},{"id":"T293","span":{"begin":504,"end":640},"obj":"Sentence"},{"id":"T294","span":{"begin":641,"end":855},"obj":"Sentence"},{"id":"T295","span":{"begin":856,"end":1063},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"6.7 SARS-CoV-2-CNS risk\nMathew reported that it might be due to the obstructions in the nervous system, which may restrict the entry of air into the lungs [108]. The virus enters the medullary neurons during the latency phase. A possible mechanism explained was that the SARS-CoV-2 might enter the olfactory lobe of the brain through nasal chambers upon inhalation and may lead to inflammation and demyelination. Later, it spreads to the whole brain due to its ability to cross the blood-brain barrier. Some neurological symptoms exhibited by the COVID-19 infection patients include nausea, vomiting, and headache (represented in Table 1). Since the SARS-CoV-2 possess the ability to cross the blood-brain barrier, it is important to design the drugs in such a way that they can cross the blood-brain barrier and scavenges the brain from viral infection. Also, it is essential to note that the respiratory illness accompanies neurological invasion by the virus, therapeutic care must be taken to prevent the viral entry into the central nervous system (CNS) [7]."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T205","span":{"begin":399,"end":412},"obj":"Phenotype"},{"id":"T206","span":{"begin":584,"end":600},"obj":"Phenotype"},{"id":"T207","span":{"begin":606,"end":614},"obj":"Phenotype"},{"id":"T208","span":{"begin":895,"end":914},"obj":"Phenotype"}],"attributes":[{"id":"A205","pred":"hp_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/HP_0011096"},{"id":"A206","pred":"hp_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/HP_0002017"},{"id":"A207","pred":"hp_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/HP_0002315"},{"id":"A208","pred":"hp_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/HP_0002086"}],"text":"6.7 SARS-CoV-2-CNS risk\nMathew reported that it might be due to the obstructions in the nervous system, which may restrict the entry of air into the lungs [108]. The virus enters the medullary neurons during the latency phase. A possible mechanism explained was that the SARS-CoV-2 might enter the olfactory lobe of the brain through nasal chambers upon inhalation and may lead to inflammation and demyelination. Later, it spreads to the whole brain due to its ability to cross the blood-brain barrier. Some neurological symptoms exhibited by the COVID-19 infection patients include nausea, vomiting, and headache (represented in Table 1). Since the SARS-CoV-2 possess the ability to cross the blood-brain barrier, it is important to design the drugs in such a way that they can cross the blood-brain barrier and scavenges the brain from viral infection. Also, it is essential to note that the respiratory illness accompanies neurological invasion by the virus, therapeutic care must be taken to prevent the viral entry into the central nervous system (CNS) [7]."}

PMC:7243768 / 41781-42844 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7243768 / 41781-42844 JSON TXT